A Practical Review of Proteasome Pharmacology
Authors:
Open Access
- 1 April 2019
- journal article
- review article
- Published by Elsevier in Pharmacological Reviews
- Vol. 71 (2) , 170-197
Abstract
The ubiquitin proteasome system (UPS) degrades individual proteins in a highly regulated fashion and is responsible for the degradation of misfolded, damaged, or unneeded cellular proteins. During the past 20 years, investigators have established a critical role for the UPS in essentially every cellular process, including cell cycle progression, transcriptional regulation, genome integrity, apoptosis, immune responses, and neuronal plasticity. At the center of the UPS is the proteasome, a large and complex molecular machine containing a multicatalytic protease complex. When the efficiency of this proteostasis system is perturbed, misfolded and damaged protein aggregates can accumulate to toxic levels and cause neuronal dysfunction, which may underlie many neurodegenerative diseases. In addition, many cancers rely on robust proteasome activity for degrading tumor suppressors and cell cycle checkpoint inhibitors necessary for rapid cell division. Thus, proteasome inhibitors have proven clinically useful to treat some types of cancer, especially multiple myeloma. Numerous cellular processes rely on finely tuned proteasome function, making it a crucial target for future therapeutic intervention in many diseases, including neurodegenerative diseases, cystic fibrosis, atherosclerosis, autoimmune diseases, diabetes, and cancer. In this review, we discuss the structure and function of the proteasome, the mechanisms of action of different proteasome inhibitors, various techniques to evaluate proteasome function in vitro and in vivo, proteasome inhibitors in preclinical and clinical development, and the feasibility for pharmacological activation of the proteasome to potentially treat neurodegenerative disease.Keywords
This publication has 271 references indexed in Scilit:
- Proteasome Inhibitors: An Expanding Army Attacking a Unique TargetChemistry & Biology, 2012
- ATP-Dependent Steps in the Binding of Ubiquitin Conjugates to the 26S Proteasome that Commit to DegradationMolecular Cell, 2010
- Selective vulnerability of neurons to acute toxicity after proteasome inhibitor treatment: Implications for oxidative stress and insolubility of newly synthesized proteinsFree Radical Biology and Medicine, 2010
- Structure of a Blm10 Complex Reveals Common Mechanisms for Proteasome Binding and Gate OpeningMolecular Cell, 2010
- Ubiquitinated Proteins Activate the Proteasome by Binding to Usp14/Ubp6, which Causes 20S Gate OpeningMolecular Cell, 2009
- Docking of the Proteasomal ATPases' Carboxyl Termini in the 20S Proteasome's α Ring Opens the Gate for Substrate EntryMolecular Cell, 2007
- Ubiquitin-Independent Degradation of Cell-Cycle Inhibitors by the REGγ ProteasomeMolecular Cell, 2007
- Distinct Ubiquitin-Ligase Complexes Define Convergent Pathways for the Degradation of ER ProteinsCell, 2006
- Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's diseaseAnnals of Neurology, 2004
- Salinosporamide A: A Highly Cytotoxic Proteasome Inhibitor from a Novel Microbial Source, a Marine Bacterium of the New Genus SalinosporaAngewandte Chemie International Edition, 2003